Lv51
1197 积分 2021-03-23 加入
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2天前
已完结
An evaluation of recaticimab for the treatment of hypercholesterolemia
2天前
已完结
Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia
2天前
已完结
Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia
2天前
已完结
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
14天前
已完结
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
14天前
已完结
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
14天前
已关闭
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
15天前
已关闭
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
16天前
已关闭
皖公网安备34019202002308
